BioTuesdays

Tag - Robert Hazlett

Axsome Therapeutics

BTIG ups Axsome Therapeutics PT to $48 from $25

BTIG raised its price target for Axsome Therapeutics (NASDAQ:AXSM) to $48 from $25 after the company announced positive Phase 2 data for its AXS-12 drug candidate for the treatment of cataplexy and excessive daytime...

NextCure

BTIG starts NextCure at buy; PT $61

BTIG initiated coverage of NextCure (NASDAQ:NXTC) with a “buy” rating and $61 price target. The stock closed at $39.84 on Nov. 25. NextCure is developing first‐in‐class medicines to treat cancer and other immune‐related...

ASLAN Pharmaceuticals

BTIG cuts ASLAN Pharma to neutral; removes PT

BTIG downgraded ASLAN Pharmaceuticals (NASDAQ:ASLN) to “neutral” from “buy” without a price target after the company posted top-line data for Varlitinib, a pan-HER inhibitor, in its Phase 3 TREETOP study in second-line...

Homology Logo

BTIG starts Homology Medicines at buy; PT $35

BTIG initiated coverage of Homology Medicines (NASDAQ:FIXX) with a “buy” rating and $35 price target. The stock closed at $19.90 on April 23. Founded in 2015, Homology is a genetic medicine company that is focused on...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.